Page last updated: 2024-12-08

hydromethylthionine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hydromethylthionine: reduced form of methylene blue [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

leucomethylene blue : A member of the class of phenothiazines that is 10H-phenothiazine in which the ring hydrogens at positions 3 and 7 have been replaced by dimethylamino groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID164695
CHEMBL ID549963
CHEBI ID134180
SCHEMBL ID109756
MeSH IDM0056989

Synonyms (34)

Synonym
leucomethylene blue
reduced methylene blue
C05721
613-11-6
panatone
n(3),n(3),n(7),n(7)-tetramethyl-10h-phenothiazine-3,7-diamine
CHEBI:134180
hydromethylthionine
leukomethylene blue
CHEMBL549963
methylene blue leuco form
methylene blue, leuco
3-n,3-n,7-n,7-n-tetramethyl-10h-phenothiazine-3,7-diamine
n,n,n',n'-tetramethyl-10h-phenothiazine-3,7-diamine
ihu4gyz2r3 ,
unii-ihu4gyz2r3
hydromethylthionine [usan]
AKOS015962343
SCHEMBL109756
2W9I
DTXSID2047985
leuco-form
leucoform
trx-0237
n3,n3,n7,n7-tetramethyl-10h-phenothiazine-3,7-diamine
hydromethylthionine [inn]
10h-phenothiazine-3,7-diamine, n3,n3,n7,n7-tetramethyl-
10h-phenothiazine-3,7-diamine, n,n,n',n'-tetramethyl-
3-n,3-n,7-n,7-n-tetramethyl-10h-phenothiazine-3,7-diamine2hbr
ZB1100
leuco methylene blue
QTWZICCBKBYHDM-UHFFFAOYSA-N
leucomethylene-blue
Q27280736

Research Excerpts

Overview

Hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed Phase 3 trials.

ExcerptReferenceRelevance
"Hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed Phase 3 trials in mild/moderate Alzheimer's disease (AD)."( Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.
Bentham, P; Gauthier, S; Kook, K; Miller, S; Schelter, BO; Wischik, CM, 2022
)
2.36
"Hydromethylthionine (HMT) is a potent inhibitor of tau aggregation in vitro and in vivo and is being developed as a possible anti-dementia medication."( Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice.
Baddeley, TC; Harrington, CR; Klein, J; Kondak, C; Leith, M; Riedel, G; Santos, RX; Wischik, CM, 2023
)
1.93
"Hydromethylthionine is a potent inhibitor of pathological aggregation of tau and TDP-43 proteins."( Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.
Baddeley, TC; Bentham, P; Bracoud, L; Ganesan, H; Gauthier, S; Hammel, J; Hardlund, J; Harrington, CR; Jia, J; Kipps, CM; Kook, K; Moebius, HJ; Murray, AD; Riedel, G; Rubino, CM; Schelter, BO; Shiells, H; Staff, RT; Storey, JMD; Vuksanovic, V; Wischik, CM; Wischik, DJ, 2020
)
2.28
"Hydromethylthionine is a potent tau aggregation inhibitor."( Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier.
Bentham, P; Harrington, CR; Schelter, BO; Shiells, H; Staff, RT; Wischik, CM, 2021
)
1.75

Effects

Hydromethylthionine has pharmacological activity on brain structure and function at the 8 mg/day dose as monotherapy or as add-on to symptomatic treatments.

ExcerptReferenceRelevance
"Hydromethylthionine has a similar concentration-response profile for effects on clinical decline and brain atrophy at the 8 mg/day dose in bvFTD as recently reported in AD. "( Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.
Baddeley, TC; Bentham, P; Bracoud, L; Ganesan, H; Gauthier, S; Hammel, J; Hardlund, J; Harrington, CR; Jia, J; Kipps, CM; Kook, K; Moebius, HJ; Murray, AD; Riedel, G; Rubino, CM; Schelter, BO; Shiells, H; Staff, RT; Storey, JMD; Vuksanovic, V; Wischik, CM; Wischik, DJ, 2020
)
2.28
"Hydromethylthionine has pharmacological activity on brain structure and function at the 8 mg/day dose as monotherapy or as add-on to symptomatic treatments. "( Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.
Baddeley, TC; Bentham, P; Bracoud, L; Ganesan, H; Gauthier, S; Hammel, J; Harrington, CR; Jia, J; Kook, K; Murray, AD; Riedel, G; Rubino, CM; Schelter, BO; Shiells, H; Staff, RT; Storey, JMD; Vuksanovic, V; Wischik, CM, 2019
)
2.23
"Hydromethylthionine has a similar concentration-response profile for effects on clinical decline and brain atrophy at the 8 mg/day dose in bvFTD as recently reported in AD. "( Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.
Baddeley, TC; Bentham, P; Bracoud, L; Ganesan, H; Gauthier, S; Hammel, J; Hardlund, J; Harrington, CR; Jia, J; Kipps, CM; Kook, K; Moebius, HJ; Murray, AD; Riedel, G; Rubino, CM; Schelter, BO; Shiells, H; Staff, RT; Storey, JMD; Vuksanovic, V; Wischik, CM; Wischik, DJ, 2020
)
2.28

Dosage Studied

ExcerptRelevanceReference
" Although Azure B is a significant impurity in methylene blue trihydrate, the amount of Azure B seen in urine samples collected from rodents dosed with methylene blue trihydrate is significantly greater than the amount seen in rodent urine spiked directly with methylene blue."( Determination of methylene blue and leucomethylene blue in male and female Fischer 344 rat urine and B6C3F1 mouse urine.
Gaudette, NF; Lodge, JW,
)
0.13
"A capillary electrophoresis method for the determination of the dye methylene blue (tetramethylthionine, MB) in human urine depending on liquid/liquid-extraction and diode array detection has been developed, validated, and applied to samples of healthy individuals, who had been dosed with methylene blue within clinical studies."( Analysis of methylene blue in human urine by capillary electrophoresis.
Borwitzky, H; Burhenne, J; Haefeli, WE, 2005
)
0.33
" This combined with a plateau at higher doses is consistent with the lack of dose-response seen in the Phase III trials."( Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.
Baddeley, TC; Bentham, P; Bracoud, L; Ganesan, H; Gauthier, S; Hammel, J; Harrington, CR; Jia, J; Kook, K; Murray, AD; Riedel, G; Rubino, CM; Schelter, BO; Shiells, H; Staff, RT; Storey, JMD; Vuksanovic, V; Wischik, CM, 2019
)
0.79
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
fluorochromeA fluorescent dye used to stain biological specimens.
bacterial xenobiotic metaboliteAny bacterial metabolite produced by metabolism of a xenobiotic compound in bacteria.
rat metaboliteAny mammalian metabolite produced during a metabolic reaction in rat (Rattus norvegicus).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
phenothiazines
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, AcetylcholinesteraseTetronarce californica (Pacific electric ray)Ki0.03310.03310.03310.0331AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1674981Protection against amyloid beta oligomer-induced cytotoxicity in human SH-SY5Y cells expressing wild-type Tau assessed as cell viability at 10 uM by MTT assay2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Discovery of biphenyl pyrazole scaffold for neurodegenerative diseases: A novel class of acetylcholinesterase-centered multitargeted ligands.
AID423541Solubility in 100 mM phosphate buffer at pH 7.02008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID423540Dissociation constant, pKa of the compound2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.
AID1399539Inhibition of congo red-induced EGFP-tagged Tau P301L mutant (unknown origin) aggregation expressed in HEK293T cells at 0.5 uM pretreated for 30 mins followed by congo red addition and measured after 24 hrs by DAPI staining-based fluorescence assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Synthesis and evaluation of 1,2,3,4-tetrahydro-1-acridone analogues as potential dual inhibitors for amyloid-beta and tau aggregation.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2012Protein science : a publication of the Protein Society, Aug, Volume: 21, Issue:8
Structural and functional characterization of the interaction of the photosensitizing probe methylene blue with Torpedo californica acetylcholinesterase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (10.81)18.7374
1990's1 (2.70)18.2507
2000's5 (13.51)29.6817
2010's15 (40.54)24.3611
2020's12 (32.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.02 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index5.39 (4.65)
Search Engine Demand Index43.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (12.82%)5.53%
Reviews1 (2.56%)6.00%
Case Studies1 (2.56%)4.05%
Observational0 (0.00%)0.25%
Other32 (82.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]